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A B S T R A C T
Background: There is evidence that increased intake of folate protects against the development of several
types of cancer. Some studies have, however, raised concern about the safety of folate in relation to cancer
risk. Here we examined the risk of maternal cancer after intake of supplemental folic acid in pregnancy.
Methods: This is a population-based cohort study comprising 429,004 women with data from the Medical
Birth Registry of Norway, the Cancer Registry of Norway, and other national registries from 1999 to 2010.
Altogether 3781 cancer cases were identiﬁed during follow-up (average 7 years). Cox proportional
hazards regression models were used to estimate hazard ratios of maternal cancer according to folic acid
use prior to and during one or two or more pregnancies as compared to no supplement use.
Results: Folic acid supplementation use had no overall effect on cancer risk in women using folic acid
supplementation in one (HR 1.08; 95% CI 1.00–1.18) or two or more pregnancies (HR 1.06; 95% CI 0.91–
1.22) (ptrend = 0.12). Analyses of 13 cancer types revealed no associations between folic acid and cancer.
Conclusion: Folic acid supplementation before and during pregnancy had no overall effect on maternal
cancer risk.
Impact: Folic acid substitution before and/or during pregnancy does not increase the short-term overall
maternal cancer risk.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Cancer Epidemiology
The International Journal of Cancer Epidemiology, Detection, and Prevention
journa l homepage: www.cancerepidemiology.net1. Introduction
Pre-gestational intake of folic acid prevents neural tube defects
(NTDs) [1–3], and in many countries health authorities recommend
women planning pregnancy to take folic acid supplementation
before and during pregnancy [2]. Mandatory food fortiﬁcation with
folic acid has been implemented in many countries but remains
controversial in others, with issues concerning cancer risk [4–7]. At
present, there is no mandatory folic acid food fortiﬁcation in Norway.
The Norwegian National Nutrition Council recommends that all
womenwho are planningpregnancyorare likely to become pregnant
use 400 mg folic acid daily from one month before pregnancy
throughout the ﬁrst three months of pregnancy [8].* Corresponding author at: Mortensen, Department of Global Public Health and
Primary Care, University of Bergen, Kalfarveien 31, N-5018 Bergen, Norway.
E-mail address: jan.mortensen@igs.uib.no (J.H.S. Mortensen).
http://dx.doi.org/10.1016/j.canep.2015.10.009
1877-7821/ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article unFolates are a group of B-vitamins important in DNA synthesis,
replication, and genomic stability [9,10]. Folic acid is the synthetic
form of folate with a substantially higher bioavailability relative to
food folate [11]. Data from human studies suggests that
consumption of high doses of folic acid, or with the highest blood
folate concentrations, have a signiﬁcantly reduced risk of
developing colon polyps or cancer [12]. However, an entirely
protective role for folate against carcinogenesis has been
questioned. Based on human and animal evidence Kim proposed
that folic acid supplementation may enhance colorectal carcino-
genesis in neoplastic foci whereas folate deﬁciency may have an
inhibitory effect [13]. Further, supraphysiologic doses of folic acid
may enhance the development of cancer in normal colorectal
mucosa, modest doses of folic acid may suppress, whereas folate
deﬁciency may predispose the normal mucosa to neoplastic
transformation [13]. So far, ﬁndings from epidemiologic studies
have not been consistent on the subject of folate and cancer risk. A
2013 meta-analysis of 13 randomized trials includingder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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prevent complications in cardiovascular disease, showed no
statistically signiﬁcant association with total cancer or sub-types
of cancer [14].
No studies on periconceptional folic acid supplementation and
maternal cancer risk have previously been conducted except for a
randomized, double-blind study published in 2004 that later was
criticized for the statistical approach and study design [15,16].
In the Medical Birth Registry of Norway, folic acid supplemen-
tation use has been registered since 1998. The aim of this study was
to examine the subsequent risk of maternal cancer after intake of
supplemental folic acid in pregnancy.
2. Material and methods
2.1. Data sources
Using the unique personal identiﬁcation number given to
citizens living in Norway, data was retrieved from the Norwegian
Central Population Registry (NCPR) with linked data from the
Medical Birth Registry of Norway (MBRN) [17], the Cancer
Registry of Norway (CRN) [18], the Norwegian Labour and Welfare
Administration (NAV) and the Norwegian National Education
Database (NUDB). MBRN is a population-based registry contain-
ing information on all births in Norway since 1967 [17]. It is based
on compulsory notiﬁcation of all deliveries from gestational week
16 (since 2002 from week 12). CRN was established in 1951 and
contains information on all new cancer cases and certain
precancerous lesions in Norway. NAV was established in
2006 after govermental reorganization of the Directorate of
Labour in Norway (founded in 1945), and holds information on
employment, health status and social beneﬁts of all individuals
with residence in Norway since 1992. Since 1970, NUDB has
registered information on all individuals’ education since
completed primary school and as far as doctoral studies in one
database.
2.2. Exposure
The MBRN’s notiﬁcation form from December 1998 onwards
has recorded information on folic acid and multivitamin supple-
mentation by using checkboxes with the items “folic acid before
pregnancy”, “folic acid during pregnancy”, “multivitamins before
pregnancy”, and “multivitamins during pregnancy”. In Norway,
folic acid supplements intended for use in pregnancy contained
0.4 mg folic acid, while most multivitamin supplements contained
0.0–0.2 mg of folic acid. The mothers were deﬁned as folic acid
users if folic acid were used before and/or during pregnancy.
Furthermore, the mothers were deﬁned as multivitamin users if
folic acid were used before and/or during pregnancy. Based on the
above information, we created two exposure variables of folic acid
use, and one exposure variable of multivitamin use; the use in
successive pregnancies (no use, use in one pregnancy, and use in
two or more pregnancies), and the total amount of folic acid from
multivitamin supplements (approximately 0.2 mg) and folic acid
supplements (0.4 mg).
2.3. Outcome
Incident cancer cases (International Classiﬁcation of Diseases
version 10 (ICD-10)) were identiﬁed through linkage with CRN. For
each mother, only the ﬁrst cancer diagnosis was used. The 13 most
frequent cancer sub-groups in our cohort were chosen. Sub-groups
of cancers included colorectal cancer (C18–21), lung cancer (C33–
34), melanoma of the skin (C43), non-melanoma skin cancer (C44),
breast cancer (C50), and cancer of the uterine cervix (C53), ovary(C56), central nervous system (C70–72, D42–43), thyroid (C73),
and other endocrine glands (C37, C74–75), Hodgkin’s lymphoma
(C81), non-Hodgkin’s lymphoma (C82–85, C96), and leukemia
(C91–95, D45–47). Cancer sites with less than 50 cases were
combined in the group “Other cancers” (C00–17, C22–26, C30–32,
C38–41, C45, C47–49, C51–52, C54, C57–58, C64–69, C76, C80, C88,
C90).
2.4. Confounders
Data on maternal year of birth, maternal age at ﬁrst childbirth in
the study period (1999–2010), maternal age at ﬁrst childbirth
(prior to start of follow-up period), parity, marital status, and
smoking habits was collected from the MBRN. Information on
maternal smoking was recorded at start and end of pregnancy (no
smoking, sometimes, daily, number of cigarettes, declined to
inform about smoking habits). The smoking data was then
combined into a single variable that contained the maximum
cigarette consumption for each woman. Information on length of
education and occupation at time of childbirth was collected from
NUDB and NAV, respectively.
2.5. Study cohort
All women living in Norway and giving birth in the period
January 1, 1999 to December 31, 2010 (429,004 women and
679,484 pregnancies) constituted our study cohort. Induced
abortions (2491) were excluded since information on vitamin
use has not been registered. Pregnancies to women who emigrated
before birth (13,733) or women who were diagnosed with cancer
before delivery (3334) were also excluded. The women were
followed from the date of their ﬁrst birth during 1999-2010 until a
cancer diagnosis, death, emigration, or end of follow-up at
December 31, 2010.
2.6. Statistical analysis
Hazard ratios (HRs) of cancer with 95% conﬁdence intervals
(95% CIs), among women using folic acid in successive pregnancies
compared to women using no folic acid, were estimated using
time-dependent Cox proportional hazard regression models [19].
Time since the ﬁrst childbirth during 1999–2010 was used as time
variable. Tests for linear trend over the categories of folic acid
supplementation were conducted.
Similar time-dependent Cox proportional hazard regression
analyses were also conducted for multivitamin use in successive
pregnancies compared to women using no multivitamins.
The Cox models were adjusted for maternal age at ﬁrst
childbirth (age at cohort entry) during 1999–2010 (<20, 20–24,
25–29, 30–34, 35–39, 40 years), maternal year of birth (1949–59,
1960–69, 1970–79, 1980–89, 1990–96), and parity (1, 2, 3, 4),
marital status (unmarried, married/registered partner/cohabitant,
divorced/widowed), education (compulsory (1st–7th class level),
intermediate (8th–12th class level), tertiary (14th–20th class
level)), occupation (10 main groups), and smoking status at the
time of birth (never, sometimes, 10 cigarettes daily, >10 cigarettes
daily, daily smoking–unknown amount). For total cancer and
breast cancer, we also adjusted for maternal age at very ﬁrst
childbirth (<20, 20–24, 25–29, 30–34, 35–39, 40 years).
For the years 2003–2010 occupational codes were available.
Occupational codes registered in 2003 were applied for births
during 1999–2002.
Since 16% of the study population had missing smoking
information, we performed multiple imputation on missing
smoking status at the time of birth according to White and
Royston [20], and Sterne and colleagues [21]. Time-dependent Cox
Table 1
Characteristics of the study population at start of follow-up, Norway, 1999–2010.
Maternal characteristics Cohort Person-years % Cancer cases (n) %
Mothers 429,004 2,933,587 100 3781 100
Maternal year of birth
1949–59 3158 31,900 1 119 3
1960–69 102,284 920,987 31 1813 48
1970–79 227,841 1,621,811 55 1640 43
1980–89 92,535 355,060 12 208 6
1990–96 3186 3829 0 1 0
Maternal age at ﬁrst childbirth in 1999–2010
<20 years 15,119 92,407 3 45 1
20–24 years 79,225 504,471 17 344 9
25–29 years 146,380 1,013,239 35 984 26
30–34 years 124,835 890,856 30 1361 36
35–39 years 52,931 365,858 12 823 22
40 10,514 66,755 2 224 6
Maternal age at ﬁrst childbirtha
<20 years 33,626 249,038 8 256 7
20–24 years 122,114 885,507 30 916 24
25–29 years 150,240 1,054,830 36 1317 35
30–34 years 78,821 497,201 17 822 22
35–39 years 21,343 120,523 4 275 7
40 years 3,105 15,631 1 59 2
Missing data 19,755 110,857 4 136 4
Folic acid use in pregnancyb
No usec 252,620 2,002,547 68 2579 68
Before pregnancy 5082 31,153 1 32 1
During pregnancy 112,874 622,961 21 801 21
Before and during pregnancy 58,428 276,926 9 369 10
Multivitamin use in pregnancyb,d
No usec 298,543 2,187,443 75 2,826 75
Before pregnancy 5,890 33,067 1 53 1
During pregnancy 79,995 467,255 16 564 15
Before and during pregnancy 44,576 245,821 8 338 9
Educationb
Compulsory (1st–7th class level) 86,530 604,712 21 692 18
Intermediate (8th–12th class level) 149,530 1,093,481 37 1418 38
Tertiary (13th–20th class level) 174,222 1,133,166 39 1571 42
Missing data 18,722 102,227 3 100 3
Occupationb,e
Armed forces and unspeciﬁed 144,109 1,154,409 39 1516 40
Legislators, senior ofﬁcials and managers 11,397 75,386 3 124 3
Professionals 21,543 118,501 4 192 5
Technicians and associate professionals 61,202 353,946 12 464 12
Clerks 27,314 192,749 7 268 7
Service workers and shop and market sales workers 97,772 605,065 21 639 17
Agricultural, forestry and ﬁshery workers 1443 9766 0 8 0
Craft and related trades workers 4175 26,800 1 46 1
Plant and machine operators and assemblers 8732 59,862 2 63 2
Elementary occupations 19,164 127,270 4 114 3
Missing data 32,153 209,833 7 347 9
Parityb
1 278,438 1,631,675 56 1751 46
2 86,528 750,522 26 1110 29
3 45,168 391,057 13 644 17
4 18,870 160,333 5 276 7
Marital statusb
Unmarried 33,345 200,844 7 214 6
Married/partnership 385,481 2,644,365 90 3449 91
Divorced 2322 16,564 1 24 1
Missing data 7856 71,814 2 94 2
Smokingb
Never 275,462 1,885,522 64 2416 64
Sometimes 12,245 85,200 3 115 3
10 cigarettes daily 49,956 367,012 13 520 14
>10 cigarettes daily 18,304 117,721 4 151 4
Daily, unknown amount 4061 27,608 1 23 1
Missing data 68,976 450,524 15 556 15
a Including births before 1999.
b At start of follow-up.
c No information on use.
d Multivitamins used in Norway contain on average 0.2 mg folic acid.
e Occupational codes registered in 2003 were applied for births during 1999–2002.
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Table 2
Cancer cases registered during follow-up (1999–2010) according to age at diagnosis
and calendar year among 429,004 women in Norway.
Cancer cases (n) %
Age at primary cancer diagnosis (years)
<20 6 0
20–24 77 2
25–29 418 11
30–34 884 23
35–39 1157 31
40 1239 33
Year of primary cancer diagnosis
1999–2001 199 5
2002–2004 630 17
2005–2007 1194 32
2008–2010 1758 46
Total 3781 100
808 J.H.S. Mortensen et al. / Cancer Epidemiology 39 (2015) 805–811proportional hazard regression analyses were then conducted on
the imputed data set.
The statistical analyses were carried out with the statistical
packages SPSS version 22 and STATA version 13 [22,23].
3. Results
The women were followed for an average of 7 years (range 0.04–
12 years), constituting 2,933,587 person-years. The mean age at
start of follow-up was 29 years (range 13–54 years). Characteristics
of the study population at start of follow-up are presented in
Table 1.
During follow-up, 3781 cancer cases were diagnosed. The mean
age at diagnosis was 37 years (range 18–56 years). Mean time
between the ﬁrst birth in the study period and cancer diagnosis
was ﬁve years (range 0.1–12 years). Breast cancer was the most
frequent cancer type in the cohort (1166 cases). A total of
343 cancer cases were grouped into the “Other” category when
the cancer site frequency was less than 50 cases. Table 2 shows
maternal age and year of primary cancer diagnosis.
Fig. 1 shows the use of supplements (folic acid, multivitamins)
and smoking related to pregnancy from 1999 to the end of the
study period in 2010. In 1999, only 18% of the women used folic
acid in pregnancy compared to 71% in 2010. Multivitamin use
increased from 19% in 1999 to 42% in 2010. Daily and intermittent0
10
20
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50
60
70
80
1999 2001 2003 
%
Folic acid use Mul 
Fig. 1. Percentage folic acid (before and/or during pregnancy), multivitamin (before 
pregnancy) among 679,484 pregnancies in Norway, 1999–2010.smoking registered among women in our cohort decreased from
26% in 1999 to 20% in 2010.
The adjusted HRs of cancer (total and sub-types) with 95 %
CIs by folic acid use (before and/or during pregnancy) in one
and two or more pregnancies compared to no folic acid use
during the study period are presented in Table 3. No increased
risk was seen for total cancer among women using folic acid in
one (HR 1.08; 95% CI 1.00–1.18) or two or more pregnancies (HR
1.06; 95% CI 0.91–1.22) (ptrend = 0.12), and other sub-types of
cancer, except for an increased risk for lung and trachea cancer
(ptrend = 0.06) and thyroid cancer (ptrend = 0.05) of borderline
signiﬁcance.
Further adjustments for multivitamin use (in the analyses of
folic acid use) showed no substantial changes in the risk estimates,
neither for total cancer nor speciﬁc sub-types (data not shown).
Analyses of total dose of folic acid (continuous variable) ingested
from multivitamin supplements (0.2 mg folic acid) and folic acid
supplements (0.4 mg folic acid) revealed no substantial changes in
the risk estimates, neither for total cancer nor speciﬁc sub-types
(data not shown).
Multivitamin use (before and/or during pregnancy) in one, or
two or more pregnancies compared to no multivitamin use were
not associated with increased risk of total cancers. However,
increased risk was seen for melanoma of the skin among women
using multivitamins in one (HR 1.19; 95% CI: 0.96–1.48), and two
or more pregnancies (HR 1.58; 95% CI: 1.05–2.38) (ptrend = 0.02).
Additionally, increased risk of non-Hodgkin’s lymphoma was
seen among multivitamin users in one (HR 1.54; 95% CI: 0.94–2.53)
and two or more pregnancies (HR 2.82; 95% CI: 1.15–6.95)
(ptrend = 0.01).
Imputed analyses (on missing smoking data) showed no
substantial changes in the risk estimates, neither for total cancer
nor speciﬁc sub-types (data not shown).
4. Discussion
The aim of this study was to evaluate the association between
the recommended folic acid supplementation use and cancer risk.
Our population-based cohort study comprising 429,004 women
with data from the national registries in Norway, showed no
signiﬁcant relationship between periconceptional folic acid use
and cancer risk.2005 2007 2009
vit amin use Smoki ng
and/or during pregnancy) and cigarette use (intermittent or daily before/during
Table 3
Hazard ratios (HR) of cancer with 95% conﬁdence intervals (95% CI) by folic acid supplementation in one, or two or more pregnancies among 429,004 women in Norway,
1999–2010.
Cancer types ICD-10 codes Number of pregnancies with folic acid use Cancer cases
(N)
Model 1 Model 2
HR CI95% ptrend HR CI95% ptrend
Total cancer 0 2269 1.00 Reference 1.00 Reference
1 1214 1.09 1.01–1.17 1.08 1.00–1.18
2 298 1.04 0.92–1.17 0.08 1.06 0.91–1.22 0.12
Colorectal C18–21 0 98 1.00 Reference 1.00 Reference
1 52 1.11 0.79–1.56 0.91 0.60–1.38
2 19 1.75 1.06–2.90 0.06 1.96 1.10–3.50 0.16
Lung and trachea C33–34 0 31 1.00 Reference 1.00 Reference
1 17 1.20 0.66–2.17 1.69 0.82–3.48
2 6 1.80 0.74–4.39 0.21 2.41 0.83–7.01 0.06
Melanoma of the skin C43 0 275 1.00 Reference 1.00 Reference
1 164 1.18 0.97–1.43 1.08 0.87–1.35
2 55 1.52 1.13–2.04 0.00 1.35 0.96–1.89 0.11
Skin, non-melanoma C44 0 34 1.00 Reference 1.00 Reference
1 16 0.98 0.54–1.78 0.79 0.39–1.63
2 1 0.26 0.04–1.92 0.31 0.29 0.04–2.17 0.20
Breast C50 0 728 1.00 Reference 1.00 Reference
1 356 1.07 0.94–1.21 1.10 0.94–1.28
2 82 0.95 0.75–1.20 0.80 0.96 0.73–1.27 0.62
Cervix uteri C53 0 269 1.00 Reference 1.00 Reference
1 151 1.09 0.89–1.33 1.06 0.83–1.34
2 37 0.93 0.66–1.32 0.85 0.93 0.63–1.39 0.99
Ovary C56 0 48 1.00 Reference 1.00 Reference
1 23 0.95 0.58–1.56 1.04 0.58–1.86
2 3 0.57 0.17–1.84 0.43 0.90 0.26–3.10 0.99
Central nervous system C70-72, D42-43 0 208 1.00 Reference 1.00 Reference
1 121 1.15 0.92–1.44 1.13 0.86–1.47
2 28 1.04 0.70–1.56 0.40 0.97 0.61–1.53 0.72
Thyroid C73 0 138 1.00 Reference 1.00 Reference
1 84 1.17 0.89–1.54 1.36 0.99–1.86
2 30 1.57 1.05–2.35 0.03 1.41 0.88–2.26 0.05
Other endocrine glands C37, C74–75 0 59 1.00 Reference 1.00 Reference
1 28 0.92 0.59–1.45 0.80 0.46–1.38
2 4 0.48 0.17–1.34 0.22 0.54 0.19–1.58 0.20
Hodgkin’s lymphoma C81 0 44 1.00 Reference 1.00 Reference
1 34 1.46 0.93–2.28 1.34 0.81–2.23
2 6 1.00 0.42–2.38 0.34 0.78 0.29–2.10 0.79
Non-Hodgkin’s lymphoma C82–85, C96 0 54 1.00 Reference 1.00 Reference
1 34 1.18 0.77–1.82 1.24 0.75–2.05
2 5 0.90 0.36–2.29 0.72 1.00 0.37–2.67 0.61
Leukaemia C91–95, D45–47 0 60 1.00 Reference 1.00 Reference
1 31 1.05 0.68–1.62 1.19 0.71–2.00
2 5 0.74 0.29–1.86 0.76 0.65 0.19–2.18 0.96
Other cancers C00–17, C22–26, 0 223 1.00 Reference 1.00 Reference
C30–32, C38–41, 1 103 0.92 0.73–1.17 1.07 0.81–1.41
C45, C47–49, C51–52, 2 17 0.65 0.39–1.07 0.11 0.92 0.53–1.58 0.93
C54, C57–58, C64–69
C76, C80, C88, C90
Model 1: Adjusted for maternal age (<20, 20–24, 25–29, 30–34, 35–39, 40 years) at ﬁrst childbirth in the study period 1999–2010.
Model 2: Further adjusted for maternal year of birth (1949–59, 1960–69, 1970–79, 1980–89, 1990–96), parity (1, 2, 3, 4), marital status (unmarried, married/registered
partner/cohabitant, divorced/widowed), education (compulsory [1st–7th class level], intermediate [8th–12th class level], tertiary [14th–20th class level]), occupation (armed
forces/unspeciﬁed, legislators, senior ofﬁcials/managers, professionals, technicians/associate professionals, clerks, service workers/shop workers/market sales workers,
agricultural/forestry/ﬁshery workers, craft/ related trades workers, plant/machine operators, assemblers/elementary occupations), and smoking (never, intermittent, 10
cigarettes daily, >10 cigarettes daily, daily smoking–unknown number of cigarettes). For total cancer and breast cancer the model was also adjusted for maternal age at ﬁrst
childbirth (<20, 20–24, 25–29, 30–34, 35–39, 40 years) prior to start of follow-up.
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Our results are in accordance with several prospective cohort
studies and meta-analyses showing no overall or site-speciﬁc
association between folic acid use and cancer risk [14,24–26].
However, there are inconsistencies in the literature regarding
folate status and the risk of cancer. Some prospective cohort
studies have found an inverse association between dietary folate
intake or blood folate concentrations and risk of cancer of the
colon, breast, ovary, and pancreas [27–32]. Contrary to these
observational studies, two randomized controlled trials found no
protective association between folic acid use (in combination with
other B-vitamins) and cancer risk (overall and site-speciﬁc)
[24,25].
Several potential mechanisms have been proposed by which
folate or the bioactive form of folic acid may increase the risk of
cancer. Folate is important for the synthesis of DNA, methylation,
and repair [9,10]. An imbalance in these three functions might play
a role in carcinogenesis. Unmetabolized folic acid may compromise
the immunological defense against cancer and augment the
growth of established cancer cells [33]. Other reports suggest that
folic acid supplementation may promote cancer cells in already
established neoplastic foci through de novo methylation of tumor
suppressor genes with consequent gene inactivation, leading to
tumor progression [5,34].
Interestingly, a potential dual modulatory role of folate on
colorectal cancer has been proposed by Kim [13]. Folic acid may
enhance the growth of cancer cells in established neoplastic foci
whereas folate deﬁciency may inhibit progression of established
colorectal neoplasms. On the other hand, in normal colorectal
mucosa, folate deﬁciency may stimulate the initial stages of
carcinogenesis in the colon and rectum, moderate doses of folic
acid use may suppress, whereas high doses of folic acid may
enhance the development of cancer [13].
The complex relationship between folate intake and colorectal
cancer risk may be further modulated by genetic variants of folate
metabolism enzymes. The enzyme methylenetetrahydrofolate
reductase (MTHFR) is involved in the folate metabolism necessary
for both DNA methylation and DNA synthesis. A common
polymorphism in the MTHFR gene (MTHFR 677C!T polymor-
phism) is connected to reduced MTHFR enzyme activity and
function that is important for the nucleotide and methylation
pathways [35]. However, the MTHFR 677C!T polymorphism
appears to decrease the risk of several adult cancer types
(colorectal, liver, uterine cervical and acute lymphocytic leukemia)
[35]. The MTHFR 677 TT genotype seems, however, to increase the
risk of esophageal, gastric and pancreatic cancer [36].
We also evaluated the association between multivitamin use
and risk of cancer. Our ﬁnding of no association between
multivitamin use and total cancer risk is supported by other
studies, reporting little or no inﬂuence from multivitamin use on
total risk of cancer, including colorectal cancer [37,38]. Though, in
sub-group analyses we found an increased risk of malignant
melanoma and non-Hodgkin’s lymphoma. These ﬁndings are in
discrepancy with a large prospective cohort study on antioxidant
supplementation that did not show increased melanoma risk [39].
However, a study by Zhang et al. in 2001 showed that multivitamin
use was associated with a higher risk of non-Hodgkin’s lymphoma
among women, but not among men, and the authors concluded
that their observed ﬁndings were the results of chance [40].
4.2. Strengths and limitations
To our knowledge, this is the largest study on cancer risk and
folic acid use among pregnant women to date. The strengths of our
study are the large cohort consisting mainly of healthy women infertile age and the use of population-based registries covering the
entire Norwegian population, assuring generalizability of our
results. The loss to follow-up was minimal.
A limitation of this study is no records on dose, frequency, or
precise duration of folic acid or multivitamin use throughout
pregnancy. However, supplemental folic acid and multivitamin use
as recorded in the MBRN, has also been used in other epidemio-
logical studies [41,42]. In this study, we could not control for other
health behaviours than smoking. Consequently, there could be
confounding from other risk factors.
Altogether 16% of the pregnancies included in the study lacked
smoking data, but imputation of missing values for smoking did
not change our estimates. Most childbearing women know the
adverse health effects of smoking to the foetus, which could reduce
the reliance of self-reported smoking habits. On the other hand,
smoking habits were documented before a possible cancer
diagnosis.
Breast cancer was the most frequent cancer type in our cohort.
Since young women at ﬁrst full-term pregnancy have a decreased
risk of developing hormone receptor positive breast cancer later
in life [43], we also adjusted risks of breast cancer and total cancer
for maternal age at her very ﬁrst birth (including ﬁrst birth before
cohort entry in 1999). Adjustments for other potentially
confounding factors (age at ﬁrst childbirth in the study period,
maternal year of birth, marital status, occupation, and smoking)
showed minor changes in estimates, which reduced the likeli-
hood of residual confounding. But, we could not adjust for other
potential confounders, such as body mass index (BMI), physical
activity, diet, alcohol intake, use of NSAIDs, exogenous hormones,
and familial cancer syndromes, because these covariates were not
available. Alcohol use, known to antagonise folate absorption and
metabolism, is unlikely an important confounder, as the
consumption of alcohol during pregnancy is generally low in
Norway [44].
5. Conclusion
Overall, we found no association between folic acid supple-
mentation and cancer risk. Our study cannot, however, assess the
long-term impact of folic acid supplementation on cancer risk. The
complex biological relation between folate and cancer needs
cautious interpretation, and additional epidemiological research is
warranted.
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